Arthur Wong, Managing Director at S&P Global Ratings, joins Remy Blaire to discuss Pfizer investing $70 billion to expand U.S. manufacturing and join a new platform called Trumprx.gov, offering Americans deep discounts on many primary care drugs. Arthur shares what impacts the Pfizer deal could have on broader drug pricing policy in the U.S., especially if other companies follow suit.
